Clinical research

Intracoronary application of abciximab in patients with ST-elevation myocardial infarction

EuroInterv.2008;3:465-469.

Jochen Wöhrle*, MD, FESC; Thorsten Nusser, MD; Christine Mayer, MD; Matthias Kochs, MD; Vinzenz Hombach, MD

Department of Internal Medicine II, University of Ulm, Ulm, Germany

Aims: Abciximab provides dose-dependent antiplatelet and anti-inflammatory properties. No specifically designed prospective studies have addressed the role of intracoronary bolus administra

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

myocardial infarctionthrombolysisreperfusionfollow-upglycoprotein iib/iiia inhibitor

Share on Facebook Share on Twitter Share on Linkedin

Latest news

NEW ISSUE

Ischaemia with non-obstructive coronary arteries, OCT vs IVUS guidance in PCI; the ILUMIEN III and ILUMIEN IV trials…

Elective Cardiac Invasive Procedures during the COVID-19 Outbreak

A. Chieffo et al.

January 8, 2021

EDITORIAL

Smoke signals – do they help to predict TAVI-associated stroke risk?

R. Kharbanda et al.

January 25, 2021

Trials Book

SCOPE 2, BASKET-SMALL 2 3 years, ALPHEUS, COMPARE-ABSORB, DUBIUS

(Thanks to the support of Biotronik)

January 13, 2021

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

JAA

This Week's JAA's: Redo-TAVI, Major bleeding in the Amulet Observational Study, OCT findings in ESR...